A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

Milestone Pharmaceuticals Inc. is a strong buy under $2 with FDA approval for Cardamyst expected in 2026, offering unique ...

A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.

The FTC sued Xlear after it marketed its spray as a covid preventative. The Trump administration dropped the suit, but the ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

MomMed, a trusted maternal and family wellness brand, today announced a strategic partnership with nasal care innovator ...

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...